Sezary syndrome: Difference between revisions
Line 31: | Line 31: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* The prevalence of sezary syndrom is exact unknown. | * The prevalence of sezary syndrom is exact unknown. | ||
* In 2005 and 2009 the incidence of sezary syndrome was estimated to be 0/08 | * In 2005 and 2009 the incidence of sezary syndrome was estimated to be 0/08 and 0/09 cases per 100,000 individuals in the United States.<ref name="pmid19279331">{{cite journal |vauthors=Bradford PT, Devesa SS, Anderson WF, Toro JR |title=Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases |journal=Blood |volume=113 |issue=21 |pages=5064–73 |date=May 2009 |pmid=19279331 |pmc=2686177 |doi=10.1182/blood-2008-10-184168 |url=}}</ref><ref name="pmid18808419">{{cite journal |vauthors=Saunes M, Nilsen TI, Johannesen TB |title=Incidence of primary cutaneous T-cell lymphoma in Norway |journal=Br. J. Dermatol. |volume=160 |issue=2 |pages=376–9 |date=February 2009 |pmid=18808419 |doi=10.1111/j.1365-2133.2008.08852.x |url=}}</ref> | ||
===Age=== | ===Age=== |
Revision as of 19:07, 1 November 2018
WikiDoc Resources for Sezary syndrome |
Articles |
---|
Most recent articles on Sezary syndrome Most cited articles on Sezary syndrome |
Media |
Powerpoint slides on Sezary syndrome |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Sezary syndrome at Clinical Trials.gov Trial results on Sezary syndrome Clinical Trials on Sezary syndrome at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Sezary syndrome NICE Guidance on Sezary syndrome
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Sezary syndrome Discussion groups on Sezary syndrome Patient Handouts on Sezary syndrome Directions to Hospitals Treating Sezary syndrome Risk calculators and risk factors for Sezary syndrome
|
Healthcare Provider Resources |
Causes & Risk Factors for Sezary syndrome |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Sezary syndrome is one of the most common subtypes of cutaneous T cell lymphoma (CTCL).
Historical Perspective
- Sezary syndrome (SS) was first described by Albert Sézary.[1]
Classification
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
- Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
Pathophysiology
- The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
- The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
- On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Clinical Features
Differentiating [disease name] from other Diseases
- [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The prevalence of sezary syndrom is exact unknown.
- In 2005 and 2009 the incidence of sezary syndrome was estimated to be 0/08 and 0/09 cases per 100,000 individuals in the United States.[2][3]
Age
- [Disease name] is more commonly observed among patients aged [age range] years old.
- Sezary syndrome is more commonly observed among elderly patients.
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected with [disease name] than [gender 2].
- The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
Race
- Sezary syndrome usually affects individuals of the whites race.[4]
- [Race 2] individuals are less likely to develop [disease name].
Risk Factors
- Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Natural History, Complications and Prognosis
- The majority of patients with [disease name] remain asymptomatic for [duration/years].
- Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
- If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].
Diagnosis
Diagnostic Criteria
- The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
Symptoms
- [Disease name] is usually asymptomatic.
- Symptoms of [disease name] may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
Physical Examination
- Patients with [disease name] usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with [disease name].
- A [positive/negative] [test name] is diagnostic of [disease name].
- An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
- Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
Imaging Findings
- There are no [imaging study] findings associated with [disease name].
- [Imaging study 1] is the imaging modality of choice for [disease name].
- On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
- [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
- [Disease name] may also be diagnosed using [diagnostic study name].
- Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
Treatment
Medical Therapy
- There is no treatment for [disease name]; the mainstay of therapy is supportive care.
- The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action 1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
- Surgery is the mainstay of therapy for [disease name].
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
- [Surgical procedure] can only be performed for patients with [disease stage] [disease name].
Prevention
- There are no primary preventive measures available for [disease name].
- Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].
References
- ↑ Steffen C (August 2006). "The man behind the eponym dermatology in historical perspective: Albert Sézary and the Sézary syndrome". Am J Dermatopathol. 28 (4): 357–67. PMID 16871044.
- ↑ Bradford PT, Devesa SS, Anderson WF, Toro JR (May 2009). "Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases". Blood. 113 (21): 5064–73. doi:10.1182/blood-2008-10-184168. PMC 2686177. PMID 19279331.
- ↑ Saunes M, Nilsen TI, Johannesen TB (February 2009). "Incidence of primary cutaneous T-cell lymphoma in Norway". Br. J. Dermatol. 160 (2): 376–9. doi:10.1111/j.1365-2133.2008.08852.x. PMID 18808419.
- ↑ Criscione VD, Weinstock MA (July 2007). "Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002". Arch Dermatol. 143 (7): 854–9. doi:10.1001/archderm.143.7.854. PMID 17638728.